Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.

Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Jason J. Luke(University of Chicago), Toshio Shimizu(Wakayama Medical University), C. Talluto(Novartis (United States)), Neeltje Steeghs(Peter MacCallum Cancer Centre), Nitya Nair(490 BioTech (United States)), Shahneen Sandhu(The University of Melbourne), Andrew Bean(Tris Pharma (United States)), Nancy Lewis(Tris Pharma (United States)), Anna Spreafico(University Health Network), Reinhard Dummer(University Hospital of Zurich), Robert J. Brown(Aduro BioTech (United States)), Sinead Dolan(Novartis (United States)), Stefan Kasper(Essen University Hospital), Damian Trujillo(Aduro BioTech (United States)), Omid Hamid(Cedars-Sinai Medical Center)
Journal of Clinical Oncology
May 20, 2019
10.1200/jco.2019.37.15_suppl.2507
Cited by 192

Related Papers

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k